Opportunistic screening using point-of-care testing leads to successful linkage to care of HBV-infected migrant populations in a low endemic country.

Hepatitis B virus (HBV) Public health Screening

Journal

Journal of virus eradication
ISSN: 2055-6640
Titre abrégé: J Virus Erad
Pays: England
ID NLM: 101654142

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 12 02 2024
revised: 22 03 2024
accepted: 25 03 2024
medline: 10 4 2024
pubmed: 10 4 2024
entrez: 10 4 2024
Statut: epublish

Résumé

In low endemic countries, screening for hepatitis B surface antigen (HBsAg) in migrants is cost-effective in reducing the disease burden of hepatitis B virus (HBV) infections, but linkage to care (LTC) remains a challenge. This study aims to guide future screening initiatives, with 3 objectives: 1. to compare LTC between different ethnic groups screened for HBsAg with point-of-care testing (POCT) in an outreach setting; 2. to estimate the proportion of HBsAg seropositivity for ethnic minorities; and 3. to investigate the association between seropositivity and HBV risk factors. Opportunistic outreach screenings using finger prick HBsAg tests were performed at civic integration programmes between 11/2017 and 09/2022. If an individual tested positive, an appointment was given immediately at the outpatient hepatology clinic for follow-up and confirmation of HBsAg positivity in blood. Dedicated personnel contacted these individuals to motivate them for further LTC, which was defined as being assessed by a hepatologist, a blood test and an abdominal ultrasound. A total of 677 people from different ethnicities (Asian, Middle Eastern and African) were serologically screened using POCT. The observed positivity for HBsAg was 3.4 % (95% CI 2.17-5.05, 23/677). Apart from ethnicity and male sex, none of the surveyed HBV risk factors were associated with HBsAg seropositivity. All HBsAg positive individuals were linked to care and assessed by a hepatologist, despite the COVID-19 pandemic increase in time to follow-up of 82 days (95% CI 51-112 days) vs. 24 days (95% CI 5-43 days, p = 0.008)).Among HBV-infected patients, 31.8% (7/22), 100 % (22/22) and 26.1% (6/23) met the criteria for treatment indication, intrafamilial transmission risk and need for hepatocellular carcinoma surveillance, respectively. The proportion of HBsAg seropositivity in ethnic minorities was 3.4%. POCT and commitment of dedicated personnel can overcome previously identified barriers resulting in a 100% LTC.

Sections du résumé

Background and aims UNASSIGNED
In low endemic countries, screening for hepatitis B surface antigen (HBsAg) in migrants is cost-effective in reducing the disease burden of hepatitis B virus (HBV) infections, but linkage to care (LTC) remains a challenge. This study aims to guide future screening initiatives, with 3 objectives: 1. to compare LTC between different ethnic groups screened for HBsAg with point-of-care testing (POCT) in an outreach setting; 2. to estimate the proportion of HBsAg seropositivity for ethnic minorities; and 3. to investigate the association between seropositivity and HBV risk factors.
Methods UNASSIGNED
Opportunistic outreach screenings using finger prick HBsAg tests were performed at civic integration programmes between 11/2017 and 09/2022. If an individual tested positive, an appointment was given immediately at the outpatient hepatology clinic for follow-up and confirmation of HBsAg positivity in blood. Dedicated personnel contacted these individuals to motivate them for further LTC, which was defined as being assessed by a hepatologist, a blood test and an abdominal ultrasound.
Results UNASSIGNED
A total of 677 people from different ethnicities (Asian, Middle Eastern and African) were serologically screened using POCT. The observed positivity for HBsAg was 3.4 % (95% CI 2.17-5.05, 23/677). Apart from ethnicity and male sex, none of the surveyed HBV risk factors were associated with HBsAg seropositivity. All HBsAg positive individuals were linked to care and assessed by a hepatologist, despite the COVID-19 pandemic increase in time to follow-up of 82 days (95% CI 51-112 days) vs. 24 days (95% CI 5-43 days, p = 0.008)).Among HBV-infected patients, 31.8% (7/22), 100 % (22/22) and 26.1% (6/23) met the criteria for treatment indication, intrafamilial transmission risk and need for hepatocellular carcinoma surveillance, respectively.
Conclusion UNASSIGNED
The proportion of HBsAg seropositivity in ethnic minorities was 3.4%. POCT and commitment of dedicated personnel can overcome previously identified barriers resulting in a 100% LTC.

Identifiants

pubmed: 38596321
doi: 10.1016/j.jve.2024.100369
pii: S2055-6640(24)00006-2
pmc: PMC11002856
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100369

Informations de copyright

© 2024 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Thomas Vanwolleghem is supported by a senior clinical investigator grant from the Research Foundation Flanders (grant number 18B2821 N). Part of these studies have been supported by grants from the Flemish Government (Centrum Medische Innovatie Vlaanderen-Hepatotrope Organismen, 2015), Gilead Sciences (Gilead BELUX Fellowship 2017) and Abbvie.

Auteurs

Erwin Ho (E)

University of Antwerp, Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Paediatrics, Antwerpen, Belgium.
Antwerp University Hospital, Department of Gastroenterology and Hepatology, Edegem, Belgium.

Axelle Vanderlinden (A)

University of Antwerp, Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Paediatrics, Antwerpen, Belgium.
Antwerp University Hospital, Department of Gastroenterology and Hepatology, Edegem, Belgium.

Liesbeth Govaerts (L)

Antwerp University Hospital, Department of Gastroenterology and Hepatology, Edegem, Belgium.

Bo De Fooz (B)

Antwerp University Hospital, Department of Gastroenterology and Hepatology, Edegem, Belgium.

Pierre Van Damme (P)

University of Antwerp, Vaxinfectio, Antwerpen, Belgium.

Peter Michielsen (P)

University of Antwerp, Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Paediatrics, Antwerpen, Belgium.
Antwerp University Hospital, Department of Gastroenterology and Hepatology, Edegem, Belgium.

Thomas Vanwolleghem (T)

University of Antwerp, Viral Hepatitis Research Group, Laboratory of Experimental Medicine and Paediatrics, Antwerpen, Belgium.
Antwerp University Hospital, Department of Gastroenterology and Hepatology, Edegem, Belgium.

Classifications MeSH